RecruitingPhase 2NCT04996875
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Studying Systemic mastocytosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cogent Biosciences, Inc.
- Principal Investigator
- Rachael Easton, MD, Ph.D.Cogent Biosciences, Inc.
- Intervention
- bezuclastinib(drug)
- Enrollment
- 140 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (30)
- University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama, United States
- Mayo Clinic Arizona, Phoenix, Arizona, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- UCLA Medical Center, Los Angeles, California, United States
- Stanford Cancer Institute, Stanford, California, United States
- Galiz Research, Hialeah, Florida, United States
- Winship Cancer Institute - Emory University, Atlanta, Georgia, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Columbia University Irving Medical Center, New York, New York, United States
- Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
- MUSC Health University Medical Center, Charleston, South Carolina, United States
- The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Huntsman Cancer Institute - University of Utah Health, Salt Lake City, Utah, United States
- Nepean Hospital, Kingswood, New South Wales, Australia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04996875 on ClinicalTrials.gov